Search the Newsreel

Nanobiotix CEO Discusses How Physics-Based Drug Delivery Could Improve Therapeutic Performance

Laurent Levy, CEO of Nanobiotix, discussed how a physics-based approach to drug delivery, exemplified by their NanoPrimer platform, could enhance therapeutic performance by optimizing particle behavior within the body. This method aims to complement existing biological therapies without adding undue complexity, offering a new …

Nanobiotix SA (NBTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Nanobiotix reports 50.8M shares outstanding and 54.5M total voting rights as of June 30, 2026

Nanobiotix S.A., a clinical biotechnology company, announced its share capital and voting rights as of June 30, 2026. The company reported 50,825,682 shares outstanding and 54,486,890 theoretical voting rights, with 54,464,772 exercisable voting rights. This disclosure aligns with French financial regulations and provides transparency …

Voting Rights and Shares Capital of the Company

Nanobiotix S.A. has published its voting rights and shares capital as of June 30, 2026, in accordance with French financial regulations. The company reported 50,825,682 shares outstanding, with 54,486,890 theoretical voting rights and 54,464,772 exercisable voting rights. Nanobiotix is a late-stage clinical biotechnology company …

Nanobiotix Reports 54.5M Theoretical Voting Rights for June 30

Nanobiotix reported its share capital and voting rights as of June 30, 2026, in compliance with French regulations. The company had 50,825,682 shares outstanding, corresponding to 54,486,890 theoretical voting rights and 54,464,772 exercisable voting rights. This disclosure is made for transparency and threshold crossing …

Qatar Investment Authority (NBTX) reports 3.53M Nanobiotix ADRs under sole control

The Qatar Investment Authority has reported beneficial ownership of 3,532,517 Nanobiotix SA Depositary Receipt S ADRs, representing 7.0% of the class. These ADRs are held with sole voting and dispositive power through its wholly-owned subsidiaries, QH Oil Investment LLC and Q Dutis Holding LLC. …

Nanobiotix SA (NBTX) Cash Flow

This article provides a detailed cash flow statement for Nanobiotix SA (NBTX), presenting annual and quarterly data from FY2012H1 to FY2024H2. It breaks down cash flows into operating, investing, and financing activities, along with key metrics like free cash flow and beginning/ending cash balances. …

Nanobiotix SA (NBTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nanobiotix SA (NBTX), detailing its support, resistance, indicators, and moving averages. It summarizes the findings from various technical indicators like MACD, RSI, and STOCH, along with moving averages, to give a "Neutral" signal for the stock based …

Nanobiotix SA (NBTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Nanobiotix SA (NBTX), focusing on its profitability and balance sheet. It includes current stock quotes, market capitalization, and links to more detailed financial and discussion content on the TradingKey platform. The content is presented as a general …

Nanobiotix SA (NBTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of dividend and stock split history for Nanobiotix SA (NBTX). It states that the company has distributed $0.00 in dividends over the past five years and indicates no dividend data is available. The article also includes current stock performance …

Nanobiotix S.A. Revenue Breakdown – NASDAQ:NBTX

This article provides a brief overview of Nanobiotix S.A.'s revenue breakdown. Last year, the company generated $37.88 million USD in revenue, with its Nanotherapeutics segment being the top performer, contributing $33.45 million USD. France was the primary geographical contributor, also accounting for $33.45 million …

Nanobiotix SA Revenue Breakdown – TURQUOISE:NANOP

Nanobiotix SA's revenue breakdown for the last year shows total generated revenue of 32.59 million EUR. The Nanotherapeutics segment was the top performer, contributing 29.64 million EUR, a significant improvement from the previous year's negative figure. France was the primary geographical contributor, matching the …

NBTX|Nanobiotix SA|Price:39.310|Chg%:-0.240

This article provides a detailed financial overview of Nanobiotix SA (NBTX), including its current stock price, market performance across various timeframes, and key financial figures. It highlights analyst ratings, indicating a "Buy" consensus with a target price of $53.00, and lists technical indicators. The …

Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at €36.20

Nanobiotix shares gained almost 5%, reaching €32.76, making it one of the strongest performers in the SBF 120. This rebound follows a week of consolidation, pushing the stock closer to its MM20 moving average. The company's annual performance remains exceptionally strong, with a 622% …

Nanobiotix Shares Soar by 4.5%, Leading the SBF 120

Nanobiotix shares gained 4.25% to €34.36, leading the SBF 120 and moving above its short-term moving averages. The company's annual performance remains strong, driven by clinical advancements of its candidate JNJ-1900 (NBTXR3) and encouraging phase 2 results. The stock's current rebound comes after a …

NBTX Q4 2025 Earnings: Significant EPS Miss Amid Clinical Pipeline Progress - Quarterly Earnings Report

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Nanobiotix (NBTX) Stock Forecast and Price Target 2026